2024
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelReal-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, Perales M, Munoz J, Fingrut W, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza A, Abid M, Hong S, Majhail N, Kharfan-Dabaja M, Khurana A, Badar T, Lin Y, Bennani N, Herr M, Hu Z, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini M. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity. Blood 2024, 143: 2722-2734. PMID: 38635762, PMCID: PMC11251200, DOI: 10.1182/blood.2023023447.Peer-Reviewed Original ResearchChimeric antigen receptorR/R LBCLNH-White patientsAxicabtagene ciloleucelZUMA-1ZUMA-7Autologous anti-CD19 chimeric antigen receptorCenter for International Blood and Marrow Transplant Research databaseAnti-CD19 chimeric antigen receptorHazard ratioOdds ratioLarge B-cell lymphomaProgression-free survivalT-cell therapyDuration of responseB-cell lymphomaCytokine release syndromeNH WhitesNH Black patientsAdjusted odds ratiosClinical trial settingClinical trial outcomesOverall survivalT cellsLBCL
2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsReal World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar O, Heim M, Brazauskas R, Hansen D, Ferreri C, Freeman C, Afrough A, Anderson L, Dhakal B, Dhanda D, Gowda L, Hashmi H, Harrison M, Kitali A, Mirza S, Patel J, Patwardhan P, Usmani S, Patel K, Ganguly S, Pasquini M. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma. Blood 2023, 142: 1027. DOI: 10.1182/blood-2023-181762.Peer-Reviewed Original ResearchCAR T-cell therapyRefractory multiple myelomaCytokine release syndromeHigh-risk cytogeneticsProgression-free survivalLow performance statusReal-world populationExtramedullary diseasePerformance statusClinical trialsResponse rateCell therapyMultivariate analysisOverall survivalMedian timeMultiple myelomaRelapsed/Refractory Multiple MyelomaTreatment of RRMMCAR T-cell doseISS stage III diseasePresence of EMDGood partial response rateLarge real-world studyPre-treated populationComplete response rate
2020
574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
Schiffer M, Perreault S, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases 2020, 7: s352-s352. PMCID: PMC7776323, DOI: 10.1093/ofid/ofaa439.768.Peer-Reviewed Original ResearchCytokine release syndromeHaploidentical hematopoietic stem cell transplantationHematopoietic stem cell transplantationFebrile neutropeniaHaplo-HSCTStem cell transplantationRelease syndromeBreakthrough infectionsCell transplantationRecurrent feverEmpiric broad-spectrum antibiotic therapyRates of FNBroad-spectrum antibiotic therapyMulti-drug resistant organismsHaplo-HSCT patientsNon-infectious complicationsPost-transplant cyclophosphamideStem cell infusionBlood culture dataPositive blood culturesBroad-spectrum antibioticsYale New Haven HealthBackground FeverAntibacterial prophylaxisSecondary endpoints